Read on Twitter
More on this news for $PSNL and checkpoint inhibitors. I'll do my best to explain but I'm not a scientist and defer to experts.
Here's the link:
https://investors.personalis.com/news-releases/news-release-details/personalis-announces-launch-neopstm-neoantigen-based-composite https://twitter.com/hiddensmallcaps/status/1339578365016203264
Here's the link:
https://investors.personalis.com/news-releases/news-release-details/personalis-announces-launch-neopstm-neoantigen-based-composite https://twitter.com/hiddensmallcaps/status/1339578365016203264
Our immune system has built-in checkpoints to identify tumors to attack. Cancer cells figured out how to fake out these checkpoints by sending false signals, which makes the tumors appear harmless.
As a result, the T-cells (anti-infection cells), don't attack the tumors.
As a result, the T-cells (anti-infection cells), don't attack the tumors.
PD-1 is one such checkpoint protein. When it is bound to PD-L1, it tells the T-cells to leave other cells alone.
Well, many tumor cells have a lot of PD-L1. So antibodies that target PD-1 or PD-L1 can block them from binding together and boost your immune response to the tumors
Well, many tumor cells have a lot of PD-L1. So antibodies that target PD-1 or PD-L1 can block them from binding together and boost your immune response to the tumors
Checkpoint inhibitors have been a hot spot for big pharma. $MRK's Keytruda and $BMY's Opdivo are the two largest drugs in this space.
This market is very large. Keytruda and Opdivo generated sales north of $15 Billion in 2019. Keytruda may become the largest drug by 2023: http://pharmatimes.com/news/keytruda_to_be_top_drug_by_2023_1312064
Eligible patients of Keytruda and Opdivo may benefit from these biomarkers Personalis developed
Eligible patients of Keytruda and Opdivo may benefit from these biomarkers Personalis developed
In their PR, $PSNL said "NEOPS significantly outperformed tumor mutational burden in predicting response to anti-PD-L1 therapy in a cohort of late-stage, unresectable melanoma patients"
The thought here is that pharma may develop companion diagnostics utilizing these biomarkers
The thought here is that pharma may develop companion diagnostics utilizing these biomarkers
Which brings me to a slide Personalis put out previously (see attached).
Anyway, I think this may be a significant catalyst for the company, moreso than I was originally thinking, but I'd defer to scientists who know more about this.
Anyway, I think this may be a significant catalyst for the company, moreso than I was originally thinking, but I'd defer to scientists who know more about this.
This is also from Personalis' most recent 10-k, highlighting the potential for diagnostics.
